Results 311 to 320 of about 623,894 (355)

Clinical effectiveness of Anlotinib combined with PD-1 inhibitors in treating advanced non-small-cell lung carcinoma. [PDF]

Am J Transl Res
Han Z, Liu W, Wang F.
europepmc   +1 more source

Neoadjuvant tepotinib in stage IIB N0 non-small cell lung carcinoma with <i>MET</i> exon 14 skipping mutation: a case report and review of the literature. [PDF]

Transl Lung Cancer Res
Reyes A, Pharaon R, Mohanty A, Kim J, Massarelli E.   +4 more
europepmc   +1 more source

E2F2 induction in related to cell proliferation and poor prognosis in non-small cell lung carcinoma.

, 2015
Li Chen, Jian Yu, Zhi Hui Lu, Wei Zhang
openalex   +1 more source

[Retracted] Metastasis‑associated protein 2 promotes the metastasis of non‑small cell lung carcinoma by regulating the ERK/AKT and VEGF signaling pathways. [PDF]

Mol Med Rep
Zhang B, Tao F, Zhang H.
europepmc   +1 more source

STIL Overexpression Is Associated with Chromosomal Numerical Abnormalities in Non-Small-Cell Lung Carcinoma Through Centrosome Amplification. [PDF]

Curr Oncol
Ohtsuka S, Kato H, Ishikawa R, Watanabe H, Miyazaki R, Katsuragi SY, Yoshimura K, Yamada H, Sakai Y, Inoue Y, Takanashi Y, Sekihara K, Funai K, Sugimura H, Shinmura K.   +14 more
europepmc   +1 more source

Impact of PM2.5 exposure on mortality and tumor recurrence in resectable non-small cell lung carcinoma. [PDF]

Sci Rep
Kosanpipat B, Wongwut T, Norrasan N, Watthanawongsa P, Phinyo P, Saeteng S, Siwachat S, Chewaskulyong B, Tantraworasin A.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Non-Small-Cell Lung Carcinoma

Drugs, 1995
Non-small-cell lung cancer (NSCLC) is one of the most common malignancies in developed countries and accounts for millions of deaths worldwide. The incidence of NSCLC correlates with smoking tobacco and is likely to increase in those countries with increasing per capita consumption of tobacco.
K T, Bastin, R, Curley
openaire   +2 more sources

Breast Metastasis from Non-Small-Cell Lung Carcinoma

Medical Oncology, 2003
Development of metastasis to the breast from lung cancer is very rare and the prognosis for such patients is poor. We present a patient who had metastasis to breast from non-small-cell lung cancer. It is important to distinguish a primary breast cancer from metastasis to the breast, as the therapy offered would be markedly different, with considerably ...
Kannan, Ramar, Hassan, Pervez, Anil, Potti, Syed, Mehdi   +3 more
openaire   +2 more sources

Molecular Diagnostics in Non-Small Cell Lung Carcinoma

Seminars in Respiratory and Critical Care Medicine, 2020
AbstractCurrent clinical practice guidelines recognize EGFR, BRAF, ALK, and ROS1 as essential molecular biomarkers, and a host of other genetic alterations as emerging biomarkers for non-small cell lung carcinoma patients. The available approaches to detecting relevant alterations in these genes are diverse and often complementary.
openaire   +2 more sources